Resistant Depression – Ketamine Infusion Trial Evaluation

Open-label, single-centre Phase I dose-escalation study (ReD-KITE) administering 0.5 mg/kg ketamine IV over 40 minutes: stage 1 once weekly for three weeks, stage 2 twice weekly for three weeks; total study duration including follow-up ~3 months.

Primary outcome assessed safety and tolerability across acute timepoints and follow-up; mood outcomes were collected repeatedly up to day 98. Results published (PubMed PMID:24699062).